Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Academic Article


  • © The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. Clinical Trials Registration NCT02263326
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Taiwo BO; Marconi VC; Berzins B; Moser CB; Nyaku AN; Fichtenbaum CJ; Benson CA; Wilkin T; Koletar SL; Colasanti J
  • Start Page

  • 1794
  • End Page

  • 1797
  • Volume

  • 66
  • Issue

  • 11